ADIL Coastlands Capital LP bought ADIAL PHARMACEUTICALS, INC. shares — SEC Form 4BUYADIAL PHARMACEUTICALS, INC.

The stock has rallied 52.91% over the last 90 days to trade at $2.63, though it remains down 66.74% over the past year and sits just 100.76% above its 52-week low of $1.31.

• •On June 11, 2026, the company announced a major pipeline overhaul and a $64M raise following the acquisition of Azora Therapeutics.
• •The trade represents the largest insider purchase in the company's history, signaling strong conviction from a 10% holder.
• •The FDA provided formal input on the Phase 3 clinical trial design for AD04 in September 2025, which is critical for the lead program's timeline.

The stock carries significant volatility risk with a beta of 1.459, and a short interest of 15.95% suggests potential selling pressure if the recovery stalls.